INTRODUCTION
Thrombin is a serine protease with a central role in haemostasis. Like trypsin, thrombin cleaves substrates on the C-terminal side of arginine residues, but its specificity is much more restricted. The structural basis for thrombin's specificity has been elucidated by crystallographic studies. Access to thrombin's active site is restricted by a surface loop that partly occludes this binding site and creates a particularly hydrophobic S # site. In addition, many of thrombin's natural substrates and inhibitors bind to a region outside the catalytic cleft termed the anion-binding exosite [1] . This exosite is a positively charged surface groove ; negatively charged regions of specific substrates (fibrinogen and thrombin receptor) and inhibitors (hirudin and heparin cofactor II) as well as its cofactor thrombomodulin interact with this site [2] . In addition to providing increased binding energy, exosite interactions also allosterically modify the active site of thrombin. Exosite-binding fragments of hirudin, heparin cofactor II and the thrombin receptor modulate the cleavage of chromogenic substrates by thrombin [3] [4] [5] [6] [7] . Similar effects are also observed with thrombomodulin [8] . It has been proposed that the conformational change induced by exosite binding is important in the cofactor activity of thrombomodulin [9] . In the absence of thrombomodulin, Protein C is a poor substrate for thrombin. This is due at least in part to the presence of aspartic residues in the P $ and P $ h positions in Protein C. Mutation of these residues greatly enhances the rate of activation of Protein C by thrombin [10, 11] . In the presence of thrombomodulin, however, Protein C Abbreviations used : Fmoc, fluoren-9-ylmethoxycarbonyl ; Mtr, 4-methoxy-2,3,6-trimethylbenzenesulphonyl ; OtBu, t-butyl ester ; pNA, p-nitroanilide ; rhir [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] , a peptide comprising residues 52-65 from the C-terminal region of recombinant hirudin. ‡ To whom correspondence should be addressed. Present address : Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3168, Australia.
activity of the Glu"*# Gln mutant ; a 5-fold decrease in the K m value for the substrate -Phe-pipecolyl-Arg-p-nitroanilide was observed in the presence of saturating concentrations of rhir&# -'&. This exosite-binding peptide also increased the k i values of chloromethanes containing a P $ aspartate with both α-thrombin and the Glu"*# Gln mutant. However, the increases in the k i values were greater with the Glu"*# Gln mutant (5-fold compared with 2-fold for α-thrombin). Thus exosite binding does not seem to mitigate putative unfavourable interactions between Glu"*# and the P $ aspartate. Moreover, increases in the k i caused by exosite binding were not unique to chloromethanes containing a P $ aspartate ; increases of the same magnitude were also observed when the P $ position was occupied by the favourable -phenylalanine in place of the unfavourable aspartate. The results obtained were consistent with exosite binding's causing changes in the conformation of the S # and\or S " sites of thrombin.
is efficiently activated by thrombin. An attractive hypothesis is that thrombomodulin's binding to the anion-binding exosite allosterically modifies thrombin's active site to allow more efficient binding of aspartate in the P $ and\or P $ h positions. The thrombin receptor also contains an aspartic residue in the P $ position as well as an exosite-binding sequence [12] and thus it also seems possible that exosite interactions modulate unfavourable active site interactions for this ligand. Indeed, the data of Ishii et al. [13] indicate that the exosite-binding sequence of the receptor overcomes the inhibitory effects of the P $ aspartic residue on thrombin's cleavage. There is evidence to suggest that the unfavourable interactions between thrombin and the P $ and\or P $ h residues of substrates involve Glu"*# in the active site of thrombin. Mutation of Glu"*# of thrombin to glutamine improves the ability of thrombin to cleave substrates with aspartate in the P $ and P $ h positions [14] . To investigate the role of exosite interactions and Glu"*# in modulating thrombin's cleavage of the thrombin receptor, we have synthesized peptidyl chloromethanes based on the thrombin receptor sequence and have determined the kinetics of inactivation of thrombin and a mutant (E192Q) in which Glu"*# is replaced by glutamine by these peptidyl chloromethanes. In addition, the effects of exosite-binding on the rate of inactivation were examined. The results indicate that Glu"*# might play a minor role in restricting thrombin's activity with substrates containing a P $ aspartate, but allosteric interactions at thrombin's exosite do not, in themselves, improve its ability to bind ligands with a P $ aspartic residue.
MATERIALS AND METHODS

Materials
All compounds used for peptide synthesis were purchased from Bachem (Bubendorf, Switzerland). Solid-phase peptides were synthesized with a Milligen 9050 PepSynthesizer and fluoren-9-ylmethyloxycarbonyl (Fmoc) strategy with the Fmoc amino acid pentafluorophenyl esters and Sasrin resin. -Phe-Pip-Arg-pNA (S-2238) (where Pip is pipecolyl and pNA represents p-nitroanilide) was purchased from Quadratech (Epsom, Surrey, U.K.) and its concentration was determined from its absorbance at 342 nm [15] . Human α-thrombin and the mutant E192Q were prepared as previously described [14, 16] . The concentrations of a peptide comprising residues 52-65 from the C-terminal region of recombinant hirudin (rhir&# -'&) and the peptidyl chloromethanes were determined by amino acid analysis. The concentrations of α-thrombin and E192Q were estimated by active site titration with p-nitrophenyl-ph-guanidinobenzoate [17] .
Synthesis of peptidyl chloromethanes
Ac-Asp-Pro-Arg-CH # Cl was prepared by standard methods as previously described [18] . The blocked nonapeptide Ac-Ala-ThrAsn-Ala-Thr-Leu-Asp-Pro-Arg-CH # Cl was prepared by a ' 6j3' procedure in which the C-terminal tripeptide diazomethane, synthesized in solution, was coupled to the N-terminal hexapeptide, which had been obtained by solid-phase synthesis [18] . 
H-Asp(OtBu)-Pro-Arg(Mtr)-CHN
Thrombin assays
These were performed in 50 mM Tris\HCl buffer, pH 7.8, containing 0.1 M NaCl and 0.2 % (w\v) poly(ethylene glycol), M r 6000, as previously described [18] . Initial-rate studies to determine the effect of rhir&# -'& on the kinetic parameters for the cleavage of -Phe-Pip-Arg-pNA used five different substrate concentrations and seven concentrations of rhir&# -'& (see Figure  1 ). For the determination of the inactivation rate constant for chloromethanes, assays contained a fixed concentration of substrate (100-400 µM) and seven different concentrations of peptidyl chloromethane.
Data analysis
The values of the inactivation rate constant (k i ) for the peptidyl chloromethanes were determined by progress-curve kinetics as previously described [18] . Progress-curve data obtained at seven different concentrations of peptidyl chloromethane (one assay did not contain inhibitor) were fitted by nonlinear regression to the following equation :
where P is the concentration of p-nitroaniline formed by cleavage of the substrate at time t, ! is the velocity of substrate cleavage in the absence of inhibitor, and kh equals k i \(1j[S]\K m ). Analysis with this equation yielded estimates of k i together with the standard errors of these estimates.
RESULTS
Effect of rhir 52-65 on the cleavage of D-Phe-Pip-Arg-pNA by E192Q
The peptide rhir&# -'& acted as an allosteric modulator for the cleavage of -Phe-Pip-Arg-pNA by E192Q. In the presence of rhir&# -'&, the K m value for -Phe-Pip-Arg-pNA decreased, whereas the k cat value remained constant. The results could be interpreted in terms of the following scheme, in which E, S and C represent E192Q, -Phe-Pip-Arg-pNA and rhir&# -'& [19] .
Because k cat did not vary in the presence of rhir&# -'&, it was assumed that β was equal to 1. In this case, the equation describing the dependence of the initial velocity ( ) on the concentrations of -Phe-Pip-Arg-pNA and rhir&# -'& is [19] :
The initial-velocity data obtained with different concentrations of -Phe-Pip-Arg-pNA and rhir&# -'& were analysed by nonlinear regression in accordance with this equation and the results of the analysis are shown in Figure 1 . This analysis yielded values for k cat , K m , K i and α that are given in Table 1 ; values for these parameters previously obtained for α-thrombin are given for comparison. In the presence of a saturating concentration of rhir&# -'&, the K m for -Phe-Pip-Arg-pNA decreased 5-fold (1\α); this decrease was twice that observed with α-thrombin ( Table 1) . [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] Assays were performed as described in the Materials and methods section. The data (shown in Figure 1) were analysed with eqn. (2) to yield the estimates of the parameters given in the 
Inactivation of thrombin by chloromethanes based on the thrombin receptor sequence effect of rhir 52-65 and the E192Q mutation
To examine the ability of interactions with the anion-binding exosite and Glu"*# to modulate the ability of thrombin to accept ligands containing a P $ aspartate, peptidyl chloromethanes based on the sequence of the thrombin receptor were synthesized and the kinetics of the inactivation of α-thrombin and E192Q were determined. A chloromethane based on the P $ -P " sequence of the thrombin receptor (Ac-Asp-Pro-Arg-CH # Cl) exhibited a relatively low inactivation rate constant (k i ) with α-thrombin (7.4i10$ M −" :s −" ; Table 2 ) ; the k i for Ac-Asp-Pro-Arg-CH # Cl was about 3000-fold lower than that observed with -Phe-ProArg-CH # Cl, one of the most rapid and best characterized peptidyl chloromethane inhibitors of thrombin [20] . The k i of Ac-AspPro-Arg-CH # Cl with E192Q was 2-fold higher than with thrombin ( Table 2 ). In contrast, -Phe-Pro-Arg-CH # Cl inactivated E192Q 5-fold more slowly than it did α-thrombin. Extension of the chloromethane to include the P ( -P " residues of the thrombin receptor (Ac-Ala-Thr-Asn-Ala-Thr-Leu-Asp-Pro-Arg-CH # Cl)
increased k i 14-fold and 9-fold with α-thrombin and E192Q respectively. The exosite-binding peptide rhir&# -'& caused an increase of 2-3-fold in k i for the chloromethanes with α-thrombin. The magnitude of the increase did not depend markedly on the sequence of the chloromethane ; it ranged from 2.2-fold with Ac-Asp-ProArg-CH # Cl to 2.9-fold with -Phe-Pro-Arg-CH # Cl. The binding of rhir&# -'& to the exosite caused slightly larger increases (approx. 5-fold) in k i with E192Q ; the observed increases with E192Q also did not depend on the sequence of the chloromethane.
DISCUSSION
In the present study we have investigated the role of exosite binding in modulating interactions with the active site of thrombin, and the involvement of Glu"*# in this process. In the structure of -Phe-Pro-ArgCH # -thrombin [21, 22] , Glu"*# is positioned such that it would make an unfavourable electrostatic interaction with a P $ aspartic residue (Figure 2) . Indeed, results obtained in this and other studies [14] suggest that the negative charge on Glu"*# does seem to play a role in restricting the ability of thrombin to bind P $ aspartic residues. Neutralization of the charge of Glu"*# in E192Q resulted in a modest (2-fold) increase in k i for peptidyl chloromethanes containing a P $ aspartate. On binding of the hirudin-derived peptide hirugen to the exosite, the side chain of Glu"*# moves from the S $ site and occupies a solvent-exposed position [23, 24] (Figure 2) . Thus it seemed possible that exosite binding by the hirudin-like region of the thrombin receptor facilitated the binding of the P $ aspartate in the active site by inducing a movement in Glu"*#. A similar model could also explain the ability of exosite binding by thrombomodulin to promote the cleavage of Protein C. The results obtained in the present study, however, do not support this hypothesis. Exosite binding of rhir&# -'& caused an allosteric change in the active site of thrombin that increased the k i values for peptidyl chloromethanes, but the same increase in k i was observed irrespective of whether the P $ position was occupied by aspartate or -phenylalanine (Table 2 ). These results indicate that exosite binding does not specifically modify the S $ site of thrombin to allow the accommodation of a P $ aspartate. Moreover, our results indicate that movement in the position of Glu"*# induced by exosite binding (Figure 2 ) does not play a role in modulating thrombin's aversion for aspartate in the P $ position. Exosite binding by rhir&# -'& also increased the k i of peptidyl chloromethanes containing a P $ aspartate with E192Q. Because Gln"*# would not make an unfavourable electrostatic interaction with a P $ aspartate, its movement would not improve the binding of the P $ aspartate. Exosite binding also seems not to affect the conformation of the S % site. A 14-fold increase in k i was observed on extension of the tripeptidyl chloromethane Ac-Asp-Pro-Arg-CH # Cl by six amino acids to give Ac-Ala-Thr-Asn-Ala-Thr-Leu-Asp-Pro-Arg-CH # Cl. Most of the increase can be accounted for by the binding of the P % Leu in the S % pocket of thrombin ; NMR studies indicate that residues on the N-terminal side of the P % leucine are disordered and probably do not make any contacts with thrombin [25] . The S % site is also occupied by the -phenylalanine residue of -Phe-Pro-Arg-CH # Cl. The fact that exosite binding caused the same increase in k i irrespective of whether the S % was occupied (Ac-Asp-Pro-Arg-CH # Cl compared with Ac-Ala-ThrAsn-Ala-Thr-Leu-Asp-Pro-Arg-CH # Cl) suggests that this site is not modified by exosite binding.
Our results are consistent with the hypothesis that the allosteric change induced by exosite binding has modified the S # and\or S " sites, leading to a better binding of proline and arginine to these 
Figure 2 Stereo view of the active-site region of thrombin showing the conformational change in Glu 192 induced by exosite binding
The receptor peptide Leu-Asp-Pro-Arg is shown in bold lines bound to the active site of thrombin (thin lines). The structure is that given by Mathews et al. [24] ; in this structure, hirugen (residues 53-64 of hirudin) is bound to the exosite. The structure of D-Phe-Pro-ArgCH 2 -thrombin [21, 22] sites. In particular, the results with E192Q support this hypothesis. Previous studies have demonstrated that the E192Q mutation dramatically affects the P " specificity of thrombin. The serpin α " -antitrypsin contains a P " methionine residue and inactivates thrombin very slowly. On mutation of Glu"*# to glutamine, the association rate constant for α " -antitrypsin with thrombin is increased 1000-fold, indicating a striking change in thrombin's P " specificity caused by the E192Q mutation [26] . The E192Q mutation also results in a change in the P # specificity of thrombin [26, 27] . Thus it seems likely that exosite binding has altered the S # and\or S " sites of E192Q, leading to a better binding of proline and arginine in these sites ; exosite binding caused a 5-fold increase in the k i values for the chloromethanes containing these P # and P " residues as well as a 5-fold decrease in K m for the substrate -Phe-Pip-Arg-pNA, which contains an analogue of proline in the P # position (Table 1) . X-ray crystallographic data also indicate that exosite binding causes a change in the S " site of thrombin. The binding of both hirudin and receptor fragments to the exosite causes a small conformational change in the segment Ala"*!-Gly"*( [24] and residues 190-192 form part of the S " pocket of thrombin.
Although our data indicate that the alteration in the position of Glu"*# caused by exosite binding (Figure 2 ) does not play a major role in allowing thrombin to accommodate an aspartate in the P $ position, other data suggest that this conformation change might be more important when an aspartate is present in both the P $ and P $ h positions. In the absence of thrombomodulin, the E192Q mutation caused a marked increase in the rate of cleavage of a peptide based on the Protein C cleavage site, which contains an aspartate in both these positions. Exosite binding by thrombomodulin, however, reduced the difference between α-thrombin and E192Q in the rate of cleavage of Protein C, suggesting that exosite binding mitigates unfavourable electrostatic interactions between Glu"*# and aspartic residues in the P $ and P $ h positions [14] .
Our observations that exosite binding does not modulate the P $ specificity of thrombin are in marked contrast with the results obtained by Ishii et al. [13] . These workers determined the EC &! values for the cleavage of mutant thrombin receptors expressed in Rat1 fibroblasts. EC &! estimates the concentration of thrombin that cleaves 50 % of the receptors on the cell surface in 15 min ; this value is related to the apparent second-order rate constant [13] proposed that exosite binding overcomes the adverse effects of the P $ aspartic residue. According to this hypothesis, a P $ aspartate is not inhibitory in the presence of exosite-binding and consequently the P $ Asp Gly mutation has no effect. However, in the absence of exosite binding, the P $ aspartate is inhibitory and its replacement improves the rate of receptor cleavage. It is difficult to correlate results obtained in solution in the present study with those obtained by Ishii et al. [13] for the cleavage of the receptor on the surface of cells. It should be noted, however, that the 20-fold inhibitory effect of the P $ aspartate observed by Ishii et al. [13] in the absence of exosite binding was much larger than the 2-6-fold effect observed in previous studies for cleavage of peptides in solution [14, 28] . A number of factors could influence the rate of cleavage of the receptor on the cell surface, including the conformation of the receptor and presence of other molecules that might modulate the interaction between the receptor and thrombin. Further studies will be necessary to resolve this discrepancy.
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